Chemomab Therapeutics (CMMB)

• Market cap: $10.5M
• 1 day: -1.75%
• 5 days: -1.18%
• 1 month: -11.58%
• 3 months: -42.27%
• 6 months: -61.82%
• Year to date: -6.15%
• 1 year: -80.19%
• 5 years: -98.92%
• 10 years: -99.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Employees: 16